Try GOLD - Free
India's Strategic Shift Towards High-Quality, Low-Cost MedTech
Bio Spectrum
|December 2025
India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.
The MedTech segment is now beginning to bloom for four reasons: policy stimulus, increased demand, favorable startup ecosystem, and increasing investments. According to the survey of medical devices clusters, 2023, the MedTech landscape has around 800 domestic medical device manufacturers, including 736 active units in 21 medical devices clusters spread over 9 states. Policy interventions like the Production Linked Incentive (PLI) scheme, Assistance to Medical Device Clusters for Common Facilities, and Medical Devices Park scheme are catalysing the domestic manufacturing of affordable (lowcost) medical devices in India. The nation's healthcare sector not only meets domestic needs but has also emerged as a global hub for medical tourism, welcoming about 2.36 million patients from 210 countries between 2019 and 2024. The startup ecosystem is fueled by Invest India MedTech initiative and the India MedTech Expo platform. There were 17 licensing deals during the India MedTech Expo 2025 - publicresearch innovations in areas such as diagnostics transferred to the private sector for scale-up. With respect to investments, between April 2000 and December 2024, the MedTech sector accumulated $3.9 billion in FDI equity, reflecting strong investor confidence in India's evolving healthcare innovation landscape.
As the fourth largest medical devices market in Asia and among the top 20 globally, India is driving a new era of low-cost medical device innovations in diagnostics and therapy that are making healthcare more accessible and equitable across all layers of the society.
India's Leap Towards Accessible Healthcare
With strong policy support-such as the National Medical Devices Policy, 2023-and a favourable ecosystem for developing lowcost, high-impact diagnostic and therapeutic solutions, India is witnessing a surge in homegrown diagnostic and therapeutic innovations.
This story is from the December 2025 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
MAHE teams up with OpenAI to integrate AI to enhance outcomes
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.
1 min
April 2026
Bio Spectrum
Jubilant Bhartia Foundation & McGill University to launch CoE in AI education
The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.
1 min
April 2026
Bio Spectrum
Heeding Auditory Warning Signs
By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).
2 mins
April 2026
Bio Spectrum
Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer
Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).
1 min
April 2026
Bio Spectrum
Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer
Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.
1 min
April 2026
Bio Spectrum
Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow
Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers
1 min
April 2026
Bio Spectrum
UK deploys new bone scanners to help prevent fractures
Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.
1 min
April 2026
Bio Spectrum
Cytiva expands Fast Trak process development and validation services facility in India
Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.
1 min
April 2026
Bio Spectrum
ΑΙ TAKES INDIAN PHARMA REINS
The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.
10 mins
April 2026
Bio Spectrum
NIH halts arm of clinical trial evaluating potential stroke treatment
The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).
1 min
April 2026
Listen
Translate
Change font size
